+------------------------------------------------------------------------------+
Momenta May Attract Hedge Funds in 2014: Bernstein 2013-11-06 14:03:06.196 GMT
By Cristin Flanagan Nov. 6 (Bloomberg) -- Chances of approval for a Momenta generic of Teva’s MS drug Copaxone look to be increasing, writes Bernstein analyst Aaron Gal, MNTA may attract significant hedge- fund interest at start of 2014. * Street not assuming take-out or chance of royalty structure separation from oper co. similar to Theravance * Now sees 50% chance Mylan will co-introduce generic in 2014 * PT raised to $24 from $20 vs Bloomberg avg PT $20 * NOTE: Nov. 4, Teva asked Supreme Court to stay appeals court ruling, while co. appealed ruling: Reuters * NOTE: In July Gal wrote, generic Copaxone in May 2014 may push Momenta to $30
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
--Editor: Stefanie Batcho-Lino
To contact the reporter on this story: Cristin Flanagan in New York at +1-212-617-8919 or cflanagan1@bloomberg.net
To contact the editor responsible for this story: Joanna Ossinger at +1-212-617-7789 or jossinger@bloomberg.net